Silence Therapeutics plc (SLN)
Silence Therapeutics plc (SLN) from its SEC filings: 2025 revenue $559,000 (-99% vs the year before), net margin -15852%, free cash flow -$62.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $559,000 |
| Revenue growth | -99% |
| Net income | -$88.6 million |
| Net margin | -15851.5% |
| Free cash flow | -$62.3 million |
| Diluted EPS | $-0.63 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -100% |
| Cash | $72.1 million |
| Share count, 1 year | +0% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.